AQR Capital Management’s Amicus Therapeutics FOLD Stock Holding History

AQR Capital Management’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$10.6M	Sell	733,198 -233,597	-24%	-$3.35M	﹤0.01%	1314
2025 Q4	$13.8M	Buy	966,795 +562,215	+139%	+$5.52M	0.01%	1076
2025 Q3	$3.19M	Buy	404,580 +292,988	+263%	+$2.09M	﹤0.01%	1710
2025 Q2	$639K	Buy	111,592 +69,138	+163%	+$446K	﹤0.01%	2470
2025 Q1	$346K	Sell	42,454 -47,805	-53%	-$442K	﹤0.01%	2623
2024 Q4	$850K	Buy	90,259 +1,413	+2%	+$14.7K	﹤0.01%	1976
2024 Q3	$949K	Buy	88,846 +1,222	+1%	+$13.3K	﹤0.01%	1879
2024 Q2	$869K	Sell	87,624 -3,422	-4%	-$35.1K	﹤0.01%	1817
2024 Q1	$1.07M	Sell	91,046 -8,845	-9%	-$113K	﹤0.01%	1659
2023 Q4	$1.42M	Sell	99,891 -11,548	-10%	-$131K	﹤0.01%	1478
2023 Q3	$1.36M	Sell	111,439 -9,227	-8%	-$119K	﹤0.01%	1485
2023 Q2	$1.52M	Buy	120,666 +2,570	+2%	+$30.5K	﹤0.01%	1384
2023 Q1	$1.31M	Buy	118,096 +3,480	+3%	+$42.9K	﹤0.01%	1435
2022 Q4	$1.4M	Buy	114,616 +12,171	+12%	+$137K	﹤0.01%	1421
2022 Q3	$1.07M	Buy	102,445 +15,967	+18%	+$178K	﹤0.01%	1491
2022 Q2	$929K	Sell	86,478 -2,413	-3%	-$19.9K	﹤0.01%	1453
2022 Q1	$842K	Hold	88,891	–	–	﹤0.01%	1616
2021 Q4	$1.03M	Hold	88,891	–	–	﹤0.01%	1548
2021 Q3	$849K	Hold	88,891	–	–	﹤0.01%	1627
2021 Q2	$857K	Hold	88,891	–	–	﹤0.01%	1651
2021 Q1	$878K	Sell	88,891 -56,821	-39%	-$880K	﹤0.01%	1611
2020 Q4	$3.36M	Buy	145,712 +29,158	+25%	+$596K	0.01%	915
2020 Q3	$1.65M	Sell	116,554 -22,129	-16%	-$323K	﹤0.01%	1200
2020 Q2	$2.09M	Sell	138,683 -6,431	-4%	-$78.4K	﹤0.01%	1139
2020 Q1	$1.34M	Sell	145,114 -6,600	-4%	-$62.7K	﹤0.01%	1223
2019 Q4	$1.48M	Sell	151,714 -21,658	-12%	-$198K	﹤0.01%	1389
2019 Q3	$1.39M	Sell	173,372 -230	-0.1%	-$2.5K	﹤0.01%	1413
2019 Q2	$2.17M	Hold	173,602	–	–	﹤0.01%	1236
2019 Q1	$2.36M	Buy	173,602 +11,593	+7%	+$142K	﹤0.01%	1252
2018 Q4	$1.55M	Sell	162,009 -39,946	-20%	-$439K	﹤0.01%	1342
2018 Q3	$2.44M	Sell	201,955 -23,463	-10%	-$328K	﹤0.01%	1318
2018 Q2	$3.52M	Sell	225,418 -5,322	-2%	-$80.5K	﹤0.01%	1168
2018 Q1	$3.47M	Buy	230,740 +1,074	+0.5%	+$16.3K	﹤0.01%	1137
2017 Q4	$3.31M	Buy	229,666 +35,744	+18%	+$491K	﹤0.01%	1179
2017 Q3	$2.92M	Buy	+193,922	New	+$2.57M	﹤0.01%	1241
2016 Q2	–	Sell	-20,155	Closed	-$170K	–	2218
2016 Q1	$170K	Sell	20,155 -27,899	-58%	-$198K	﹤0.01%	2132
2015 Q4	$466K	Sell	48,054 -41,163	-46%	-$371K	﹤0.01%	1900
2015 Q3	$1.25M	Sell	89,217 -19,107	-18%	-$300K	﹤0.01%	1330
2015 Q2	$1.53M	Buy	108,324 +18,124	+20%	+$218K	﹤0.01%	1309
2015 Q1	$981K	Buy	90,200 +17,800	+25%	+$157K	﹤0.01%	1420
2014 Q4	$602K	Buy	72,400 +2,700	+4%	+$18.5K	﹤0.01%	1885
2014 Q3	$415K	Buy	+69,700	New	+$365K	﹤0.01%	2019

Other funds holding FOLD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

AQR Capital Management's FOLD Position: Q1 2026 in Review

AQR Capital Management reduced its Amicus Therapeutics (FOLD) stake by 24% in Q1 2026, selling an estimated $3.35M and leaving 733,198 shares worth $10.6M. The position accounts for ﹤0.01% of the portfolio, ranked #1314.

AQR Capital Management first reported a position in FOLD in Q3 2014 and has held it in 42 quarters since. The position peaked at $13.8M in Q4 2025. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

AQR Capital Management held 733,198 shares of Amicus Therapeutics worth $10.6M as of Q1 2026.
AQR Capital Management sold 233,597 Amicus Therapeutics shares in Q1 2026, an estimated $3.35M.
Amicus Therapeutics made up ﹤0.01% of AQR Capital Management's portfolio in Q1 2026, its #1314 holding.
AQR Capital Management first reported a position in Amicus Therapeutics in Q3 2014 and has held it in 42 quarters since.
AQR Capital Management's Amicus Therapeutics position peaked at $13.8M in Q4 2025.
298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on AQR Capital Management's 13F filing for Q1 2026, filed 15 May 2026.